Holland C Detke1, Melissa P DelBello2, John Landry3, Roland W Usher4. 1. Eli Lilly and Co., Indianapolis. Electronic address: detkehc@lilly.com. 2. Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati. 3. Eli Lilly Canada Inc., Toronto. 4. Eli Lilly and Co., Indianapolis.
Abstract
OBJECTIVE: To assess the efficacy and safety of olanzapine/fluoxetine combination (OFC) for the acute treatment of bipolar depression in children and adolescents. METHOD: Patients 10 to 17 years of age with bipolar I disorder (BP-I), depressed episode, baseline Children's Depression Rating Scale-Revised (CDRS-R) total score ≥40, Young Mania Rating Scale (YMRS) total score ≤15, and YMRS-item 1 ≤2 were randomized to OFC (6/25-12/50 mg/day olanzapine/fluoxetine; n = 170) or placebo (n = 85) for up to 8 weeks of double-blind treatment. The primary efficacy measure was mean change in CDRS-R using mixed-model repeated-measures methodology. RESULTS: Baseline-to-week-8 least-squares mean change in CDRS-R total score was greater for OFC-treated patients than for placebo-treated patients (-28.4 versus -23.4, p = .003; effect size = .46), with between-group differences statistically significant at week 1 (p = .02) and all subsequent visits (all p < .01). Rates of and times to response and remission were statistically significantly greater for OFC- than for placebo-treated patients. The most frequent treatment-emergent adverse events in the OFC group were weight gain, increased appetite, and somnolence. Mean weight gain at patient's endpoint was significantly greater for OFC- than for placebo-treated patients (4.4 kg versus 0.5 kg, p < .001). Treatment-emergent hyperlipidemia was very common among OFC-treated patients. Abnormal increases in hepatic analytes, prolactin, and corrected QT interval (QTc) were also common or very common but generally not clinically significant. CONCLUSION: In this study, OFC was superior to placebo, and has been approved by the US Food and Drug Administration (FDA) for the acute treatment of bipolar I depression in patients 10 to 17 years of age. Benefits should be weighed against the risk of adverse events, particularly weight gain and hyperlipidemia. Clinical trial registration information-A Study for Assessing Treatment of Patients Ages 10-17 with Bipolar Depression; http://clinicaltrials.gov; NCT00844857.
RCT Entities:
OBJECTIVE: To assess the efficacy and safety of olanzapine/fluoxetine combination (OFC) for the acute treatment of bipolar depression in children and adolescents. METHOD:Patients 10 to 17 years of age with bipolar I disorder (BP-I), depressed episode, baseline Children's Depression Rating Scale-Revised (CDRS-R) total score ≥40, Young Mania Rating Scale (YMRS) total score ≤15, and YMRS-item 1 ≤2 were randomized to OFC (6/25-12/50 mg/day olanzapine/fluoxetine; n = 170) or placebo (n = 85) for up to 8 weeks of double-blind treatment. The primary efficacy measure was mean change in CDRS-R using mixed-model repeated-measures methodology. RESULTS: Baseline-to-week-8 least-squares mean change in CDRS-R total score was greater for OFC-treated patients than for placebo-treated patients (-28.4 versus -23.4, p = .003; effect size = .46), with between-group differences statistically significant at week 1 (p = .02) and all subsequent visits (all p < .01). Rates of and times to response and remission were statistically significantly greater for OFC- than for placebo-treated patients. The most frequent treatment-emergent adverse events in the OFC group were weight gain, increased appetite, and somnolence. Mean weight gain at patient's endpoint was significantly greater for OFC- than for placebo-treated patients (4.4 kg versus 0.5 kg, p < .001). Treatment-emergent hyperlipidemia was very common among OFC-treated patients. Abnormal increases in hepatic analytes, prolactin, and corrected QT interval (QTc) were also common or very common but generally not clinically significant. CONCLUSION: In this study, OFC was superior to placebo, and has been approved by the US Food and Drug Administration (FDA) for the acute treatment of bipolar I depression in patients 10 to 17 years of age. Benefits should be weighed against the risk of adverse events, particularly weight gain and hyperlipidemia. Clinical trial registration information-A Study for Assessing Treatment of Patients Ages 10-17 with Bipolar Depression; http://clinicaltrials.gov; NCT00844857.
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Jay A Salpekar; Paramjit T Joshi; David A Axelson; Shauna P Reinblatt; Gayane Yenokyan; Abanti Sanyal; John T Walkup; Benedetto Vitiello; Joan L Luby; Karen Dineen Wagner; Nasima Nusrat; Mark A Riddle Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-10-08 Impact factor: 8.829
Authors: Benjamin I Goldstein; Boris Birmaher; Gabrielle A Carlson; Melissa P DelBello; Robert L Findling; Mary Fristad; Robert A Kowatch; David J Miklowitz; Fabiano G Nery; Guillermo Perez-Algorta; Anna Van Meter; Cristian P Zeni; Christoph U Correll; Hyo-Won Kim; Janet Wozniak; Kiki D Chang; Manon Hillegers; Eric A Youngstrom Journal: Bipolar Disord Date: 2017-09-25 Impact factor: 6.744
Authors: Daniel J Walker; Melissa P DelBello; John Landry; Deborah N D'Souza; Holland C Detke Journal: Child Adolesc Psychiatry Ment Health Date: 2017-07-12 Impact factor: 3.033
Authors: Maurizio Pompili; Ross J Baldessarini; Alberto Forte; Denise Erbuto; Gianluca Serafini; Andrea Fiorillo; Mario Amore; Paolo Girardi Journal: Int J Mol Sci Date: 2016-10-11 Impact factor: 5.923